FR2285145B1 - - Google Patents

Info

Publication number
FR2285145B1
FR2285145B1 FR7528837A FR7528837A FR2285145B1 FR 2285145 B1 FR2285145 B1 FR 2285145B1 FR 7528837 A FR7528837 A FR 7528837A FR 7528837 A FR7528837 A FR 7528837A FR 2285145 B1 FR2285145 B1 FR 2285145B1
Authority
FR
France
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
FR7528837A
Other languages
French (fr)
Other versions
FR2285145A1 (fr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GD Searle and Co Ltd
GD Searle LLC
Original Assignee
GD Searle and Co Ltd
GD Searle LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GD Searle and Co Ltd, GD Searle LLC filed Critical GD Searle and Co Ltd
Publication of FR2285145A1 publication Critical patent/FR2285145A1/fr
Application granted granted Critical
Publication of FR2285145B1 publication Critical patent/FR2285145B1/fr
Granted legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Metal Rolling (AREA)
FR7528837A 1974-09-20 1975-09-19 Composes immunologiques et procede de leur preparation Granted FR2285145A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB41037/74A GB1509707A (en) 1974-09-20 1974-09-20 Immunological compounds

Publications (2)

Publication Number Publication Date
FR2285145A1 FR2285145A1 (fr) 1976-04-16
FR2285145B1 true FR2285145B1 (enrdf_load_stackoverflow) 1980-05-30

Family

ID=10417824

Family Applications (1)

Application Number Title Priority Date Filing Date
FR7528837A Granted FR2285145A1 (fr) 1974-09-20 1975-09-19 Composes immunologiques et procede de leur preparation

Country Status (7)

Country Link
JP (1) JPS5161640A (enrdf_load_stackoverflow)
DE (1) DE2541931A1 (enrdf_load_stackoverflow)
DK (1) DK141773B (enrdf_load_stackoverflow)
FR (1) FR2285145A1 (enrdf_load_stackoverflow)
GB (1) GB1509707A (enrdf_load_stackoverflow)
NL (1) NL7511089A (enrdf_load_stackoverflow)
SE (1) SE7510505L (enrdf_load_stackoverflow)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4067971A (en) * 1976-05-13 1978-01-10 The Procter & Gamble Company Therapeutic composition
JPS54132503A (en) * 1978-04-07 1979-10-15 Kayaku Antibiotic Research Co Immune globulin combined neocarcinostatin
JPS5592325A (en) * 1978-12-29 1980-07-12 Kureha Chem Ind Co Ltd Antitumor agent and its preparation
JPS5665828A (en) * 1979-11-02 1981-06-03 Kureha Chem Ind Co Ltd Antitumor agent
JPS5665829A (en) * 1979-11-02 1981-06-03 Kureha Chem Ind Co Ltd Antitumor agent
US4315851A (en) 1978-12-29 1982-02-16 Kureha Kagaku Kogyo Kabushiki Kaisha Pharmaceutical composition having antitumor activity
DE3167679D1 (en) * 1980-03-31 1985-01-24 Inst Int Pathologie Cellulaire Pharmaceutical forms, their preparation and compositions containing the same
JPS58118520A (ja) * 1982-01-09 1983-07-14 Hidematsu Hirai 抗腫瘍性蛋白複合体およびその製造法
JPS59186924A (ja) * 1983-04-08 1984-10-23 Kureha Chem Ind Co Ltd ヒト免疫グロブリン結合抗腫瘍剤
GB2148299B (en) * 1983-09-01 1988-01-06 Hybritech Inc Antibody compositions of therapeutic agents having an extended serum half-life
DE3513572A1 (de) * 1985-04-16 1986-10-16 Karl Prof. Dr.med. 7302 Ostfildern Theurer Herstellung von praeparaten zur spezifischen beeinflussung der humoralen und zellulaeren immunreaktion
JPS62228025A (ja) * 1985-12-27 1987-10-06 Teijin Ltd 抗体複合体の製造方法
WO1988007553A1 (en) * 1987-03-26 1988-10-06 Teijin Limited Process for preparing antibody complex
US5773435A (en) * 1987-08-04 1998-06-30 Bristol-Myers Squibb Company Prodrugs for β-lactamase and uses thereof
AU649275B2 (en) * 1990-11-06 1994-05-19 Bristol-Myers Squibb Company Prodrugs for beta-lactamase and uses thereof
DE4122210C2 (de) * 1991-07-04 1999-04-01 Deutsches Krebsforsch Konjugate aus tumoraktiver Verbindung und Serumalbumin sowie Verfahren zu deren Herstellung und ihre Verwendung

Also Published As

Publication number Publication date
SE7510505L (sv) 1976-03-22
DK141773B (da) 1980-06-16
FR2285145A1 (fr) 1976-04-16
DK141773C (enrdf_load_stackoverflow) 1980-11-03
GB1509707A (en) 1978-05-04
JPS5161640A (en) 1976-05-28
DK422475A (enrdf_load_stackoverflow) 1976-03-21
NL7511089A (nl) 1976-03-23
DE2541931A1 (de) 1976-04-01

Similar Documents

Publication Publication Date Title
FR2261783B1 (enrdf_load_stackoverflow)
DK141773C (enrdf_load_stackoverflow)
FR2263054B1 (enrdf_load_stackoverflow)
AU495821B2 (enrdf_load_stackoverflow)
AU495844B2 (enrdf_load_stackoverflow)
FI215974A7 (enrdf_load_stackoverflow)
AU7253374A (enrdf_load_stackoverflow)
AU6599874A (enrdf_load_stackoverflow)
BG20147A1 (enrdf_load_stackoverflow)
BG19923A1 (enrdf_load_stackoverflow)
CH583100A5 (enrdf_load_stackoverflow)
CH573179A5 (enrdf_load_stackoverflow)
CH567956A5 (enrdf_load_stackoverflow)
CH566759A5 (enrdf_load_stackoverflow)
CH1130374A4 (enrdf_load_stackoverflow)
BG20448A1 (enrdf_load_stackoverflow)
BG20229A1 (enrdf_load_stackoverflow)
BG20227A1 (enrdf_load_stackoverflow)
BG20187A1 (enrdf_load_stackoverflow)
BG20186A1 (enrdf_load_stackoverflow)
AU481544A (enrdf_load_stackoverflow)
BG20164A1 (enrdf_load_stackoverflow)
CH598618A5 (enrdf_load_stackoverflow)
BG20145A1 (enrdf_load_stackoverflow)
BG20143A1 (enrdf_load_stackoverflow)

Legal Events

Date Code Title Description
ST Notification of lapse